Chen C, et al. - In this analysis, researchers assessed the effect and cost-effectiveness of introduction of 13-valent PCV (PCV13) vaccination globally. They evaluated the incremental cost-effectiveness ratio of PCV13 introduction by integrating two models: an ecological model for anticipating the effect of PCV on childhood invasive pneumococcal disease and a decision-tree model for anticipating a variety of clinical presentations and economic outcomes under vaccination and no-vaccination strategies. They estimate that global use of PCV13 could prevent 0·399 million child deaths and 54·6 million disease episodes per year. The global cost of PCV vaccination is expected to be around $16 billion annually. The results highlight the value of Gavi's support for the introduction of PCV in low-income countries and efforts to improve the affordability of PCVs in countries that are not eligible for or transition from Gavi support.